Praxis Precision Medicines annual stock-based compensation
2019
2020
2021
2022
2023
2024
2025
Praxis Precision Medicines Stock-Based Compensation Growth & History (PRAX)
Praxis Precision Medicines's stock-based compensation was $33.9M for fiscal 2025.
View full Praxis Precision Medicines company overviewPraxis Precision Medicines annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $33.9M | −$7.4M | −17.94% |
| 2024 | 2024-12-31 | $41.4M | $16.5M | +66.39% |
| 2023 | 2023-12-31 | $24.9M | −$3.7M | −13.07% |
| 2022 | 2022-12-31 | $28.6M | $5.9M | +26.00% |
| 2021 | 2021-12-31 | $22.7M | $17.5M | +335.48% |
| 2020 | 2020-12-31 | $5.2M | $4.5M | +680.09% |
| 2019 | 2019-12-31 | $668,000 | — | — |
Praxis Precision Medicines quarterly stock-based compensation
Q3.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $11.3M | $3.5M | +45.55% |
| Q1 2026 | 2026-03-31 | $17.1M | $8.3M | +94.76% |
| Q4 2025 | 2025-12-31 | $9.9M | $1.4M | +15.90% |
| Q3 2025 | 2025-09-30 | $7.4M | −$5.0M | −40.10% |
| Q2 2025 | 2025-06-30 | $7.8M | $1.9M | +32.19% |
| Q1 2025 | 2025-03-31 | $8.8M | −$5.7M | −39.30% |
| Q4 2024 | 2024-12-31 | $8.6M | $2.8M | +49.76% |
| Q3 2024 | 2024-09-30 | $12.4M | $6.7M | +115.72% |
| Q2 2024 | 2024-06-30 | $5.9M | $103,000 | +1.78% |
| Q1 2024 | 2024-03-31 | $14.5M | $6.9M | +90.64% |
| Q4 2023 | 2023-12-31 | $5.7M | −$640,000 | −10.05% |
| Q3 2023 | 2023-09-30 | $5.8M | −$967,000 | −14.37% |
| Q2 2023 | 2023-06-30 | $5.8M | −$1.8M | −24.12% |
| Q1 2023 | 2023-03-31 | $7.6M | −$293,000 | −3.72% |
| Q4 2022 | 2022-12-31 | $6.4M | $260,000 | +4.26% |
| Q3 2022 | 2022-09-30 | $6.7M | $209,000 | +3.21% |
| Q2 2022 | 2022-06-30 | $7.6M | $2.2M | +40.94% |
| Q1 2022 | 2022-03-31 | $7.9M | $3.2M | +69.01% |
| Q4 2021 | 2021-12-31 | $6.1M | $2.3M | +59.59% |
| Q3 2021 | 2021-09-30 | $6.5M | $5.6M | +584.26% |
| Q2 2021 | 2021-06-30 | $5.4M | $5.1M | +1794.74% |
| Q1 2021 | 2021-03-31 | $4.7M | $4.5M | +3074.15% |
| Q4 2020 | 2020-12-31 | $3.8M | — | — |
| Q3 2020 | 2020-09-30 | $953,000 | $677,000 | +245.29% |
| Q2 2020 | 2020-06-30 | $285,000 | — | — |
| Q1 2020 | 2020-03-31 | $147,000 | — | — |
| Q3 2019 | 2019-09-30 | $276,000 | — | — |
Praxis Precision Medicines stock-based compensation trends
Over the last five fiscal years, Praxis Precision Medicines's stock-based compensation increased from $5.2M to $33.9M, a change of $28.7M. The latest reported quarter, Q2 2026, shows $11.3M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Praxis Precision Medicines source filings ↗